Prevalence and Incidence of Neuromyelitis Optica Spectrum Disorder in Korea: Population Based Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hye Lim | - |
dc.contributor.author | Kim, Jae Young | - |
dc.contributor.author | Seok, Jin Myoung | - |
dc.contributor.author | Hong, Yoon-Ho | - |
dc.contributor.author | Lim, Nam Gu | - |
dc.contributor.author | Shin, Ha Young | - |
dc.contributor.author | Kim, Byung-Jo | - |
dc.contributor.author | Hwang, Soon-Young | - |
dc.contributor.author | Min, Ju-Hong | - |
dc.contributor.author | Kim, Byoung Joon | - |
dc.date.accessioned | 2021-08-31T01:00:01Z | - |
dc.date.available | 2021-08-31T01:00:01Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-05-04 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/56040 | - |
dc.description.abstract | Background: Although neuromyelitis optica spectrum disorder (NMOSD) is known to be a rare disease, its prevalence and incidence have not yet been studied in Korea. We performed a population-based study to examine the prevalence and incidence of NMOSD in Korea using data from the Korean National Health Insurance (NHI) claims database. Methods: Data from 2013 to 2017 were obtained, with a washout period set as 2013 and 2014. The prevalence and incidence of NMOSD in 2016 and 2017 were calculated using population census data. Subjects were divided into 5 groups at 15-year intervals, depending on the age at which the diagnostic code was entered. The relative risk (RR) for each age group was compared with the oldest (>= 60 years) age group. Results: The overall prevalence was estimated to be 3.36 and 3.56 per 100,000 individuals, with an incidence of 0.41 and 0.65 per 100,000 individuals-year in 2016 and 2017, respectively. The mean age was 43.08 (standard deviation, 14.56) years, and the ratio of male to females was 1:4.7. The incidence was higher in female individuals aged between 30 and 59 years (RR, 2.8-3.05; P< 0.05). Conclusion: Nationwide prevalence of NMOSD in Korea was 3.36 and 3.56/100,000 and its incidence was 0.41 and 0.65/100,000-year in 2016 and 2017 respectively. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.subject | CLINICAL-FEATURES | - |
dc.subject | EPIDEMIOLOGY | - |
dc.title | Prevalence and Incidence of Neuromyelitis Optica Spectrum Disorder in Korea: Population Based Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Hye Lim | - |
dc.contributor.affiliatedAuthor | Kim, Byung-Jo | - |
dc.identifier.doi | 10.3346/jkms.2020.35.e115 | - |
dc.identifier.scopusid | 2-s2.0-85084076297 | - |
dc.identifier.wosid | 000531022300002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.35, no.17 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 35 | - |
dc.citation.number | 17 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002584153 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | CLINICAL-FEATURES | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordAuthor | Neuromyelitis Optica Spectrum Disorder | - |
dc.subject.keywordAuthor | NMOSD | - |
dc.subject.keywordAuthor | Prevalence | - |
dc.subject.keywordAuthor | Incidence | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.